Immunotherapy against melanoma and other cancers

Abstract

A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.

1 . A method of treating a patient who has melanoma, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide, wherein said peptide consists of the amino acid sequence of SEQ ID NO: 1, 4, or 41, wherein the peptide is in a complex with an MHC molecule. 
     
     
         2 . The method of  claim 1 , wherein the T cells are autologous to the patient. 
     
     
         3 . The method of  claim 1 , wherein the T cells are obtained from a healthy donor. 
     
     
         4 . The method of  claim 1 , wherein the T cells are derived from tumor infiltrating lymphocytes or peripheral blood mononuclear cells. 
     
     
         5 . The method of  claim 1 , further comprising expanding T cells in vitro. 
     
     
         6 . The method of  claim 1 , wherein the MHC molecule is a class I molecule. 
     
     
         7 . The method of  claim 1 , wherein the composition further comprises an adjuvant. 
     
     
         8 . The method of  claim 7 , wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23. 
     
     
         9 . The method of  claim 1 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells, in vitro, with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide. 
     
     
         10 . The method of  claim 9 , wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide. 
     
     
         11 . The method of  claim 10 , wherein the antigen presenting cell is a dendritic cell or a macrophage. 
     
     
         12 . The method of  claim 9 , further comprising stimulating the activated T cells in the presence of an anti-CD28 antibody and IL-12 to clonally expand the T cells. 
     
     
         13 . The method of  claim 1 , wherein the population of activated T cells comprises CD8-positive cells. 
     
     
         14 . The method of  claim 7 , wherein the adjuvant comprises IL-2. 
     
     
         15 . The method of  claim 7 , wherein the adjuvant comprises IL-7. 
     
     
         16 . The method of  claim 7 , wherein the adjuvant comprises IL-12. 
     
     
         17 . The method of  claim 7 , wherein the adjuvant comprises IL-15. 
     
     
         18 . The method of  claim 7 , wherein the adjuvant comprises IL-21. 
     
     
         19 . The method of  claim 1 , wherein the T cells are derived from tumor infiltrating lymphocytes. 
     
     
         20 . The method of  claim 1 , wherein the T cells are derived from peripheral blood mononuclear cells.